Table 1.

Patient characteristics and analysis of overall survival in cohort 1

Prognostic factorn%% Dead1-year survival rate (95% CI) (%)2-year survival rate (95% CI) (%)Pa
All patients94100.076.645.4(35.0–55.9)23.3(13.7–32.8)
Gender0.861
 Male6063.878.342.6(29.7–55.5)22.9(11.0–34.7)
 Female3436.273.550.7(33.3–68.1)23.4(7.5–39.3)
Age0.274
 ≤55 y4648.978.339.4(24.8–53.9)18.8(6.0–31.5)
 >55 y4851.175.051.3(36.6–66.0)27.7(13.8–41.6)
M-category0.012
 M1a or M1b2628.065.462.8(43.4–82.2)43.5(22.8–64.2)
 M1c6772.082.138.0(26.0–50.0)13.7(4.1–23.3)
 Missing data1
NY-ESO-1–specific T cells<0.001
 Present4952.165.360.4(46.1–74.7)32.8(17.8–47.8)
 Absent4547.988.929.5(15.8–43.1)13.6(2.9–24.4)
Melan-A–specific T cells0.101
 Present3739.473.055.9(39.7–72.1)32.6(16.2–49.1)
 Absent5760.678.938.2(24.8–51.5)16.9(5.9–27.9)
Tregs0.64
 ≤7%4654.880.443.8(28.7–59.0)17.7(5.2–30.2)
 >7%3845.278.943.8(27.8–59.8)26.5(12.0–41.0)
 Missing data10
MDSCs0.011
 ≤11%4851.179.230.4(16.4–44.3)15.8(3.0–28.6)
 >11%4648.973.959.9(45.6–74.3)30.0(15.9–44.0)
  • aP values are results of log-rank tests excluding cases with missing values.